Michael Morrissey is President and Chief Executive Officer of Exelixis, a role he has held since 2000. He joined the company in 1994 and led its evolution from a discovery-stage biotech into a fully integrated commercial oncology company. Under his leadership, Exelixis discovered, developed, and commercialized cabozantinib, which achieved multiple FDA approvals in kidney cancer, hepatocellular carcinoma, and differentiated thyroid cancer, becoming the company’s primary revenue driver through global partnerships and direct commercialization.
Dr. Morrissey has guided Exelixis into late-stage clinical development and sustained profitability, building internal clinical, regulatory, manufacturing, and commercial capabilities and leading major strategic collaborations. He has served on multiple industry and nonprofit boards and is recognized for long-term, science-driven leadership in oncology drug development.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
